M&A Deal Summary |
|
|---|---|
| Date | 2021-04-01 |
| Target | Zdravlje |
| Sector | Life Science |
| Buyer(s) | Frontier Pharma |
| Sellers(s) | Teva Pharmaceutical Industries |
| Deal Type | Divestiture |
SEARCH BY
Try For Free 7-Day Free Trial
Frontier Pharma is a U.K.-based specialist pharmaceutical investor and operator founded by M. Levent Selamoglu and Kiren Naidoo. The company has several decades of industry experience across Europe, the Middle East, and Africa ("EMEA"). The group is well-known for its capabilities across oral solids, injectables and topical pharmaceutical forms, API production, and experience as a contract manufacturer for a range of multinationals.
| DEAL STATS | # |
|---|---|
| Overall | 1 of 1 |
| Sector (Life Science) | 1 of 1 |
| Type (Divestiture) | 1 of 1 |
| Country (Serbia) | 1 of 1 |
| Year (2021) | 1 of 1 |
| Category | Company |
|---|---|
| Founded | 1901 |
| Sector | Life Science |
| Employees | 35,001 |
| Revenue | 15.8B USD (2023) |
Teva Pharmaceutical Industries is a provider of pharmaceutical company, committed to increasing access to high-quality healthcare by developing, producing and marketing affordable generic drugs as well as innovative and specialty pharmaceuticals and active pharmaceutical ingredients. Teva Pharmaceutical Industries was founded in 1901 and is based in Tel Aviv, Israel.
| DEAL STATS | # |
|---|---|
| Overall | 8 of 9 |
| Sector (Life Science) | 7 of 8 |
| Type (Divestiture) | 8 of 8 |
| Country (Serbia) | 1 of 1 |
| Year (2021) | 1 of 2 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2018-02-01 |
Thermamex
London, United Kingdom Theramex is a global specialty pharmaceutical company dedicated to women and their health. The Company markets a broad range of branded and branded generic products across 50 countries around the world. The portfolio, which is dedicated to women's health, focuses on contraception, fertility, menopause and osteoporosis and includes key brands such as Ovaleap®, Zoely®, Seasonique®, Actonel®, Estreva® and Lutenyl®. Thermamex is based in London, United Kingdom. |
Sell | $703M |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2021-07-29 |
Immuneering
Cambridge, Massachusetts, United States Immuneering is a trusted advisor to pharmaceutical companies, pioneering new analyses to identify biological insights that improve patients’ lives. Immuneering’s team of experts provides advanced data analysis services using state-of-the-art technologies including proprietary algorithms. The company is a rapidly growing company with seven years of experience analyzing data sets ranging from gene expression (microarray) data, to single-nucleotide polymorphism (SNP) data, to protein concentration data, to clinical metadata, to next-generation sequencing (NGS) data including RNA seq, exome sequencing, and whole-genome sequencing. Using these data sets, Immuneering captures difficult-to-find signals, generates biological hypotheses, and designs follow-up studies, contributing to the development of medicines for patients with a wide range of serious diseases. Immuneering was formed in 2008 and is based in Cambridge, Massachusetts. |
Sell | - |
